A bill to amend the Controlled Substances Act to schedule MGM-15 and MGM-16 as schedule I controlled substances, and to amend the controlled Substances Act to schedule synthetic 7-hydroxymitragynine, and Mitragynine Pseudoindoxyl, as a Schedule I above a specific threshold under the controlled substance act, and to expand enforcement actions against drug manufacturers and distributors of emerging synthetic opioids, commonly known as gas station heroin.

S. 5383, introduced in the Senate on August 8, 2026, by Sen. Bernie Moreno (R-OH), would amend the Controlled Substances Act to classify several kratom-derived compounds as controlled substances. Specifically, it would place MGM-15 and MGM-16 into Schedule I, and would schedule synthetic 7-hydroxymitragynine and mitragynine pseudoindoxyl as Schedule I substances above a specified threshold amount. The bill would also expand enforcement authority against manufacturers and distributors of these and similar emerging synthetic opioid products, sometimes referred to as "gas station heroin."

The bill would primarily affect manufacturers, distributors, and retailers of products containing these compounds, as well as federal drug enforcement agencies tasked with regulating and prosecuting violations. Consumers and sellers of kratom-derived or synthetic opioid-like products could also be affected depending on how the substances are ultimately defined and enforced.

The bill's full legislative text has not yet been published, so the specific thresholds, definitions, and enforcement mechanisms are not yet publicly available. As of the latest action on August 8, 2026, the bill has only been introduced in the Senate. Next steps would typically include referral to a Senate committee, such as the Judiciary Committee, for review before any further action, such as a committee vote or floor consideration, could occur.

Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.